These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 30556959)

  • 1. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects.
    Ino H; Doi Y; Liefaard L; Cookson L; Chen C; Itoh H; Igarashi H; Nakano A
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):612-618. PubMed ID: 30556959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
    Wechalekar A; Antoni G; Al Azzam W; Bergström M; Biswas S; Chen C; Cheriyan J; Cleveland M; Cookson L; Galette P; Janiczek RL; Kwong RY; Lukas MA; Millns H; Richards D; Schneider I; Solomon SD; Sörensen J; Storey J; Thompson D; van Dongen G; Vugts DJ; Wall A; Wikström G; Falk RH
    BMC Cardiovasc Disord; 2022 Feb; 22(1):49. PubMed ID: 35152886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
    Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
    Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Richards D; Millns H; Cookson L; Lukas MA
    Orphanet J Rare Dis; 2022 Jul; 17(1):259. PubMed ID: 35810311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.
    Richards D; Bamford M; Liefaard L; Haque N; Lewis G; Storey J; Fernando D; Kumar S; Thompson D; Holmes DS
    Br J Pharmacol; 2020 Apr; 177(8):1853-1864. PubMed ID: 31877231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
    Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
    Muehlan C; Boehler M; Brooks S; Zuiker R; van Gerven J; Dingemanse J
    J Psychopharmacol; 2020 Mar; 34(3):326-335. PubMed ID: 31642731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega-3-Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single-Blind, Randomized, Placebo-Controlled Trial.
    Noda Y; Nilsson C; Shimada H; Kim H; Lundström T; Yajima T
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):177-187. PubMed ID: 28597973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study.
    Chen Q; Hu C; Liu Y; Liu Y; Wang W; Zheng H; Rong L; Jia J; Sun S; Yu C; Liu YM
    PLoS One; 2017; 12(5):e0177425. PubMed ID: 28493932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study.
    Hunt H; Donaldson K; Strem M; Zann V; Leung P; Sweet S; Connor A; Combs D; Belanoff J
    Clin Pharmacol Drug Dev; 2018 May; 7(4):408-421. PubMed ID: 28967708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
    Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
    Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
    Xuan D; McBride S; Wastall P; Porcari A; DiCarlo L; Boyd RA
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):13-26. PubMed ID: 27119575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
    Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.